EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Temporal Trends of Metastatic Prostate Cancer in the Prostate‐Specific Membrane Antigen Positron Emission Tomography Era in the United States

Leonardo Quarta iD, Maximilian Filzmayer iD, Michele Petix, Filippo Orlandi, Jordan A Goyal iD, Felix K H Chun, Matteo Ferro, Salvatore Micali, Shahrokh F Shariat, Francesco Barletta iD, Armando Stabile, Giorgio Gandaglia und 4 weitere

The Prostate · 2026

DOI: 10.1002/pros.70212 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Prostate, 2026. Verfasst von Leonardo Quarta und 15 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Prognostics and Health Outcomes Unit, University of Montréal Health Center, Division of Urology, Montréal, Québec, Canada. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Positron-Emission Tomography, Antigens, Surface, Glutamate Carboxypeptidase II. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Temporal trends of metastatic prostate cancer (mPCa) in the prostate‐specific membrane antigen positron emission tomography (PSMA PET) era in the United States are not known.

Methods

In the Surveillance, Epidemiology, and End Results (SEER) database (2018–2022), all PCa patients were identified. Estimated annual percentage change (EAPC) and multivariable logistic regression (MLR) models tested the effect of the PSMA PET era (2021–2022) on mPCa rate and its substages (M1a, M1b, M1c) rates.

Results

Overall, 236,723 PCa patients were identified. Of those, 20,450 (8.6%) harbored mPCa. mPCa rate increased from 7.9% in 2018 to 9.4% in 2022 (EAPC: +4.7%, p = 0.019). In MLR model, PSMA PET era independently predicted 1.1‐fold ( p < 0.001) increase in mPCa. Within mPCa patients, 1,564 (8.0%), 14,806 (72.0%), and 4,080 (20.0%) harbored M1a, M1b, and M1c substages. M1a and M1b substages rates increased in PSMA PET era (M1a: from 6.3% in 2018 to 9.1% in 2022, EAPC: +9.3%, p = 0.009; M1b: from 70.3% in 2018 to 74.7% in 2022, EAPC: +1.7%, p = 0.043), but not M1c (from 23.3% in 2018 to 16.2% in 2022, EAPC: −8.7%, p = 0.036). In MLR models, PSMA PET era independently predicted 1.3‐fold increase ( p < 0.001) in M1a, 1.2‐fold increase ( p < 0.001) in M1b, but 0.7‐fold ( p < 0.001) decrease in M1c.

Conclusion

The introduction of PSMA PET resulted in an increase in the proportion of mPCa patients in the United States. Within those, M1a and M1b substages increased, but M1c decreased. These observations suggest a stage migration phenomenon, where low burden mPCa (M1a and M1b) is diagnosed more frequently at the expense of high burden mPCa (M1c).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsPositron-Emission TomographyAntigens, SurfaceGlutamate Carboxypeptidase IIMaleHumansUnited StatesAgedSEER ProgramNeoplasm MetastasisMiddle Aged

Stichwörter der Autor:innen

PSMA PETSEER databasemetastaticprostate cancerstage migration

Substanzen

Antigens, SurfaceGlutamate Carboxypeptidase IIFOLH1 protein, human

Autor:innen und Institutionen

  • Cancer Prognostics and Health Outcomes Unit, University of Montréal Health Center, Division of Urology, Montréal, Québec, Canada.
  • Division of Experimental Oncology/Unit of Urology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Vita-Salute San Raffaele University, Milan, Italy.
  • Department of Urology, University Hospital, Goethe University Frankfurt, Frankfurt am Main, Germany.
  • Department of Urology, ASST Santi Paolo e Carlo, Milan, Italy.
  • Università degli Studi di Milano, Milan, Italy.

ORCID-Profile: Leonardo Quarta, Maximilian Filzmayer, Jordan A Goyal, Francesco Barletta

Zitieren

APA

Quarta, L., Filzmayer, M., Petix, M., Orlandi, F., Goyal, J. A., Chun, F. K. H., Ferro, M., Micali, S., Shariat, S. F., Barletta, F., Stabile, A., Gandaglia, G., Montorsi, F., Saad, F., Briganti, A., & Karakiewicz, P. I. (2026). Temporal Trends of Metastatic Prostate Cancer in the Prostate‐Specific Membrane Antigen Positron Emission Tomography Era in the United States. The Prostate. https://doi.org/10.1002/pros.70212

Vancouver

Quarta L, Filzmayer M, Petix M, Orlandi F, Goyal JA, Chun FKH, et al. Temporal Trends of Metastatic Prostate Cancer in the Prostate‐Specific Membrane Antigen Positron Emission Tomography Era in the United States. The Prostate. 2026. doi:10.1002/pros.70212

BibTeX
@article{Quarta2026,
  author = {Quarta, Leonardo and Filzmayer, Maximilian and Petix, Michele and Orlandi, Filippo and Goyal, Jordan A and Chun, Felix K H and Ferro, Matteo and Micali, Salvatore and Shariat, Shahrokh F and Barletta, Francesco and Stabile, Armando and Gandaglia, Giorgio and Montorsi, Francesco and Saad, Fred and Briganti, Alberto and Karakiewicz, Pierre I},
  title = {Temporal Trends of Metastatic Prostate Cancer in the Prostate‐Specific Membrane Antigen Positron Emission Tomography Era in the United States},
  journal = {The Prostate},
  year = {2026},
  doi = {10.1002/pros.70212}
}
Kostenlos starten →